Drug Price Trends for VANDAZOLE VAGINAL

Average Pharmacy Cost for VANDAZOLE VAGINAL

These are average pharmacy acquisition costs (net of discounts) from a US national survey

Drug Name	NDC	Price/Unit ($)	Unit	Date
VANDAZOLE VAGINAL 0.75% GEL	00245-0860-70	0.34510	GM	2026-04-22
VANDAZOLE VAGINAL 0.75% GEL	00245-0860-70	0.35109	GM	2026-03-18
VANDAZOLE VAGINAL 0.75% GEL	00245-0860-70	0.35298	GM	2026-02-18

VANDAZOLE VAGINAL Market Analysis and Financial Projection

Last updated: February 16, 2026

What Is VandaZole Vaginal?

VandaZole Vaginal is a formulation of metronidazole intended for intravaginal use, primarily for such conditions as bacterial vaginosis (BV) and trichomoniasis. It is marketed as a treatment option with localized delivery to minimize systemic side effects, aligning with standard practice for vaginal antimicrobials.

Market Overview

Disease Prevalence and Patient Demographics

• Bacterial vaginosis (BV): Affects approximately 29% of women aged 14-49 in the U.S., translating to an estimated 20 million cases annually [1].
• Trichomoniasis: Estimated 3.7 million infections in the U.S. annually, predominantly among women of reproductive age [2].

Current Treatment Landscape

• Established therapies include oral metronidazole and clindamycin.
• Topical formulations have gained favor for localized treatment, offering fewer systemic effects.
• VandaZole Vaginal enters a market with significant established competition, including:
  • Flagyl (metronidazole): Oral and topical forms.
  • Clindesse: Clindamycin gel.
  • Metrogel Vaginal: Metronidazole gel.

Market Size Valuation

• The European and North American markets for vaginal antimicrobials combined are valued at approximately US$800-900 million as of 2022 [3].
• Given the increasing shift toward topical formulations, the global market for topical vaginal antibiotics is projected to grow at 4-6% annually through 2030, driven by rising prevalence and patient preference for localized therapy.

Price Projections

Current Pricing for Similar Formulations

Drug Name	Formulation	Typical Wholesale Price (per dose)	Market Notes
Flagyl Vaginal	Gel (1g)	US$10-15	Widely used, low-cost option.
Clindesse	Vaginal Cream (100g)	US$50-70	Prescription strength, positioned as premium.
Metrogel Vaginal	Gel (5g)	US$15-25	Competitive topical option.

Projected Pricing for VandaZole Vaginal

Based on formulations with similar active ingredients and delivery methods, VandaZole Vaginal will likely be priced within the existing range:

• Introductory price: US$10–12 per dose.
• Market positioning: Slight premium over generics, justifying differentiation via efficacy, patient compliance, or formulation advantages.
• Potential adjustments: Prices could decline to US$8–10 per dose amid increased competition or as patent exclusivity wanes.

Revenue Estimates

Assuming a conservative market penetration:

Assumption	Calculation	Projected Revenue (US$ millions)
10% of the BV market in the U.S. (20 million cases/year)	2 million treatments annually	US$20-25 million
Price per dose: US$10–12

If marketed across North America and Europe, where BV prevalence is similar, global revenues could reach US$50-100 million annually, contingent on approval status and reimbursement.

Regulatory and Market Entry Considerations

• Regulatory approval: Pending or granted FDA approval would influence launch timing.
• Reimbursement: Coverage decisions and formulary placements significantly impact market adoption.
• Competition: Existing patent protections for key formulations could delay generic entry, supporting higher pricing initially.

Key Market Drivers and Challenges

• Growing demand for localized vaginal therapies.
• Rising antibiotic resistance prompting the development of novel formulations.
• Competition from existing generics constrains premium pricing.
• The need for strong clinical data demonstrating efficacy and safety to justify premium pricing.

Key Takeaways

• VandaZole Vaginal targets a large, growing market influenced by disease prevalence and patient preferences for topical formulations.
• Entry pricing is expected to align with existing products, US$10–12 per dose, with potential to decrease over time.
• Revenue potential in North America and Europe combined is US$50-100 million annually, depending on regulatory and market dynamics.
• The competitive landscape favors generic and over-the-counter alternatives, potentially limiting premium pricing initially.
• Market growth will be driven by increasing awareness, better diagnostic protocols, and new formulations that address resistance or side-effect concerns.

FAQs

1. What are key factors influencing VandaZole Vaginal’s market success?
   Clinical efficacy, safety profile, pricing strategy, regulatory approval, and reimbursement policies.

2. How does the pricing of VandaZole Vaginal compare to existing options?
   It is likely to be priced similarly or slightly higher initially, US$10–12 per dose, to reflect potential differentiation.

3. What are regulatory hurdles for VandaZole Vaginal?
   Approvals depend on clinical trial data demonstrating safety and efficacy, with potential delays if biosimilar or generic competitors submit similar formulations.

4. Can resistance impact the market for VandaZole Vaginal?
   Yes. Resistance to metronidazole could limit efficacy; ongoing surveillance and clinical data are critical.

5. What opportunities exist beyond the primary indications?
   Possible expansion into additional Vaginal tract infections or localized formulations for other gynecological conditions.

---

References

[1] CDC. Bacterial Vaginosis. 2022.
[2] CDC. Trichomoniasis Factsheet. 2022.
[3] MarketWatch. Women’s Vaginal Antimicrobials Market Report. 2022.